MARLBOROUGH, Mass.--(BUSINESS WIRE)--
Advanced Cell Technology, Inc. ("ACT"; OTCBB:ACTC), a leader in the field of regenerative medicine, announced today that the company’s Chief Scientific Officer, Robert Lanza, MD, has been nominated to receive the prestigious Il Leone di San Marco award in Medicine. For thirty-three years, the Italian Heritage and Culture Committee of the Bronx and Westchester has acknowledged outstanding Americans in fields such as the Performing Arts, Entertainment, Medicine, Journalism, Literature, Playwriting, Government, Science, Academia or Business. Past honorees have included Stanley Tucci, Paul Giamatti, Paul Sorvino, Danny Aiello, Armand Assante, Tony Danza, Susan Lucci, Dion DiMucci, Phil Ramone, Bart Giamatti, and Rudy Giuliani.
Dr. Lanza is one of only four people who will receive this year’s Il Leone di San Marco Award for their “many talents and great accomplishments” who represent the best in Italian-American culture. The other three honorees are Regis Philbin (Entertainment), Roma Torre (Theater Criticism), and Michael Gargiulo (Broadcast Journalism). The award in Medicine will be presented to Dr. Lanza on Sunday September 29th at the Davenport Club on Long Island Sound, New York. In addition to the award presentation, there will be musical performances by Giada Valenti, Eugene Ruffolo, and Luigi Moneta & Gayle Scott.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit http://www.advancedcell.com.
Statements in this news release regarding future financial and operating results, the relevance and applicability of clinical trials in animals to studying the effect of products in humans, future growth in animal and human research and development programs, potential new applications of and expanded indications covering our technology, the effects of donorless sources of stem cells on potency and the risk of communicable diseases in the manufacturing context, the existence and size of potential or existing market opportunities for the company, the effect of the company’s products on the medical needs and quality of life of pets, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for and limited sources of future capital, failures or delays in obtaining regulatory approval of products, risks inherent in the development and commercialization of potential products, reliance on new and unproven technology in the development of products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company’s periodic reports, including the Quarterly Report on Form 10-Q for the three months ended June 30, 2013. Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. There can be no assurance that the Company’s clinical trials will be successful.
- Health Care Industry
- Advanced Cell Technology
- regenerative medicine
- Robert Lanza
James Young, 212-732-4300
David Schull, 212-845-4271